Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Skin, Hair & Pigment

PT-141 (Bremelanotide)

A cyclic heptapeptide melanocortin receptor agonist, the active metabolite of Melanotan II, studied in central nervous system pathways of sexual arousal.

Education Hub

Pre-clinical mechanism

Preferential agonist at MC3R and MC4R. Animal models suggest activation of central melanocortin pathways implicated in sexual response.

Key pre-clinical findings

  • RECONNECT phase-3 studies: improvement in validated sexual-desire measures in adult premenopausal women (Kingsberg et al., 2019).

Primary literature

Bremelanotide for the treatment of hypoactive sexual desire disorder

Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer